Statements (26)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
antiviral drug |
| gptkbp:administeredBy |
oral
|
| gptkbp:approvedBy |
gptkb:FDA
2018 |
| gptkbp:ATCCode |
J05AX25
|
| gptkbp:brand |
gptkb:Xofluza
|
| gptkbp:CASNumber |
1985606-14-1
|
| gptkbp:chemicalFormula |
C27H23F2N3O7
|
| gptkbp:developedBy |
gptkb:Japan
|
| gptkbp:discoveredBy |
gptkb:Shionogi_&_Co.
|
| gptkbp:eliminationHalfLife |
79.1 hours
|
| https://www.w3.org/2000/01/rdf-schema#label |
Baloxavir marboxil
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:marketedAs |
gptkb:Xofluza
|
| gptkbp:mechanismOfAction |
cap-dependent endonuclease inhibitor
|
| gptkbp:pregnancyCategory |
not recommended
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
bronchitis
nausea diarrhea |
| gptkbp:synonym |
S-033188
|
| gptkbp:target |
gptkb:influenza_virus
|
| gptkbp:usedFor |
treatment of influenza
|
| gptkbp:bfsParent |
gptkb:Influenza_Virus
|
| gptkbp:bfsLayer |
6
|